Breaking News Instant updates and real-time market news.

OFIX

Orthofix

$55.04

-0.27 (-0.49%)

07:04
04/04/19
04/04
07:04
04/04/19
07:04

Orthofix announces full two-year outcomes from IDE study of M6-C cervical disc

Orthofix Medical announced the full two-year outcomes from its U.S. Investigational Device Exemption study of the M6-C artificial cervical disc. The data demonstrates that patients treated with the M6-C artificial cervical disc had significant improvements in neck and arm pain, function and quality of life scores. Additionally, these patients had a significant difference in the reduction of pain and opioid medications use when compared to anterior cervical discectomy and fusion patients. At 24 months, patients in the ACDF group who were still using pain medications had a seven times higher rate of opioid use than those in the M6-C disc group. A prospective, non-randomized, concurrently controlled clinical trial, the M6-C IDE study was conducted at 23 sites in the United States with an average patient age of 44 years. The study evaluated the safety and effectiveness of the M6-C artificial cervical disc compared to ACDF for the treatment of single level symptomatic cervical radiculopathy with or without cord compression. The overall success rate for the protocol-specified primary endpoint for the M6-C disc patients was 86.8 percent at 24 months and 79.3 percent in the control group. This data statistically demonstrates that cervical disc replacement with the M6-C disc is not inferior to treatment with ACDF. fSecondary outcomes at 24 months include: Patients who received the M6-C disc demonstrated statistically significant improvement in the Neck Disability Index as measured at week six and months three, six, 12 and 24. Meaningful clinical improvement was seen in the following pain scores: 91.2 percent of patients who received the M6-C disc reported an improvement in neck pain compared to 77.9 percent in patients who underwent the ACDF procedure. 90.5 percent of the M6-C patients reported improvement in arm pain scores compared to 79.9 percent in ACDF patients. Prior to surgery, 80.6 percent of the M6-C disc patients and 85.7 percent of the ACDF patients were taking some type of pain medication for the treatment of their cervical spine condition. At 24 months, the rate of M6-C patients who were still taking some type of pain medication dropped to 14.0 percent compared to 38.2 percent of the ACDF patients. Of these, there was a seven times higher rate of opioid use with the ACDF patients than with patients who received the M6-C disc. There was a statistically significant difference in the average mean surgery time - 74.5 minutes for patients receiving the M6-C disc versus 120.2 minutes for those patients having the ACDF procedure. In addition, there was a statistically significant difference in the mean length of hospital stay - 0.61 days for the M6-C patients versus 1.10 days for ACDF patients. Subsequent surgery at the treated level was needed in 4.8 percent of the ACDF patients compared to 1.9 percent of the M6-C disc patients. There were no device migrations reported in the study. Overall patients receiving the M6-C disc reported a 92-percent satisfaction rate with the surgery, and 93 percent said they would have the surgery again. There were 3.8 percent serious adverse events related to the device or procedure in the M6-C disc group versus 6.1 percent in the ACDF group. The M6-C disc received FDA approval in February 2019 based on the results of this study.

  • 09

    May

  • 10

    May

OFIX Orthofix
$55.04

-0.27 (-0.49%)

02/26/19
BTIG
02/26/19
DOWNGRADE
BTIG
Neutral
Orthofix downgraded to Neutral from Buy at BTIG
BTIG analyst Ryan Zimmerman downgraded Orthofix to Neutral after its Q4 earnings miss, announcement of CEO retirement, guidance for high spending, an no expected acceleration in Q1 revenue growth. The analyst expects the stock trade range-bound until there is more clarity on commercialization of the company's M6-C disk replacement that was recently approved by the FDA. While he has a positive view of the M6-C program, Zimmerman also believes that the company's expectations for double-digit revenue growth are "ambitious".
08/07/18
CANT
08/07/18
NO CHANGE
Target $66
CANT
Overweight
Orthofix price target raised to $66 from $62 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Orthofix International to $66 saying that while the Q2 results were "messy," the earnings beat and raise keeps him positive. The sales miss and lower guidance raise concerns, Bijou tells investors in a research note, pointing out that he would like to see sequential progress on the sales disruptions. However, he calls Orthofix's earnings beat "impressive" and keeps an Overweight rating on the shares.
05/31/18
CANT
05/31/18
INITIATION
Target $62
CANT
Overweight
Orthofix initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou started Orthofix with an Overweight rating and $62 price target. The analyst believes the recent share pullback provides a good entry point, especially ahead of more details on the benefit of re-domiciling to the U.S.
05/31/18
CANT
05/31/18
INITIATION
Target $62
CANT
Overweight
Orthofix initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Orthofix with an Overweight and $62 price target.

TODAY'S FREE FLY STORIES

RMBS

Rambus

$11.84

-0.065 (-0.55%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Rambus reports Q1 adjusted EPS (8c), may not compare to consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

ADC

Agree Realty

$64.35

-0.96 (-1.47%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Agree Realty reports Q1 Core FFO 74c, consensus 74c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 04

    Jun

HMTV

Hemisphere Media

$14.78

0.09 (0.61%)

, DISH

Dish

$33.70

-1.2 (-3.44%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Hot Stocks
Hemisphere Media: Cinelatino reaches renewal agreement with DISH Network »

Hemisphere Media (HMTV)…

HMTV

Hemisphere Media

$14.78

0.09 (0.61%)

DISH

Dish

$33.70

-1.2 (-3.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 06

    May

  • 21

    May

GES

Guess

$16.68

-0.39 (-2.28%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Guess affirms Q1 outlook »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.54

3.26 (1.83%)

16:06
04/22/19
04/22
16:06
04/22/19
16:06
Hot Stocks
Facebook names State Department's Jennifer Newstead as General Counsel »

Facebook announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    Jun

ROKU

Roku

$58.20

1.51 (2.66%)

16:04
04/22/19
04/22
16:04
04/22/19
16:04
Initiation
Roku initiated at Susquehanna »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 22

    May

TCFC

Community Financial

$28.96

0.06 (0.21%)

16:03
04/22/19
04/22
16:03
04/22/19
16:03
Earnings
Community Financial reports Q1 EPS 70c, consensus 64c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$76.64

-1.07 (-1.38%)

15:55
04/22/19
04/22
15:55
04/22/19
15:55
Options
NetApp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 09

    Jul

RTRX

Retrophin

$19.99

-0.08 (-0.40%)

15:51
04/22/19
04/22
15:51
04/22/19
15:51
Conference/Events
Retrophin management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 04

    May

  • 08

    May

  • 05

    Jun

  • 30

    Jun

BDRBF

Bombardier

$0.00

(0.00%)

15:43
04/22/19
04/22
15:43
04/22/19
15:43
Periodicals
Bombardier sees higher sales from modernizing existing rail cars, Reuters says »

Bombardier expects higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 05

    Jun

DHI

D.R. Horton

$45.61

-0.815 (-1.76%)

15:40
04/22/19
04/22
15:40
04/22/19
15:40
Options
DR Horton draws call sellers after an analyst downgrade, ahead of earnings »

DR Horton draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NBL

Noble Energy

$27.78

0.66 (2.43%)

15:38
04/22/19
04/22
15:38
04/22/19
15:38
Hot Stocks
Noble Energy raises quarterly dividend 9% to 12c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 03

    May

RMBS

Rambus

$11.82

-0.08 (-0.67%)

15:34
04/22/19
04/22
15:34
04/22/19
15:34
Options
Rambus options imply 9.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

TSLA

Tesla

$263.63

-9.62 (-3.52%)

, SSNLF

Samsung

$0.00

(0.00%)

15:24
04/22/19
04/22
15:24
04/22/19
15:24
Hot Stocks
Tesla confirms neural processor design custom by Tesla »

During Tesla's…

TSLA

Tesla

$263.63

-9.62 (-3.52%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

SBUX

Starbucks

$75.23

-0.84 (-1.10%)

15:24
04/22/19
04/22
15:24
04/22/19
15:24
Hot Stocks
Chinese Starbucks competitor Luckin Coffee files for U.S. listing »

According to the filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WHR

Whirlpool

$139.79

0.75 (0.54%)

15:19
04/22/19
04/22
15:19
04/22/19
15:19
Options
Whirlpool options imply 10.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

TSLA

Tesla

$263.10

-10.15 (-3.71%)

, NVDA

Nvidia

$188.97

2.71 (1.46%)

15:17
04/22/19
04/22
15:17
04/22/19
15:17
Hot Stocks
Tesla able to make more specific solution than Nvidia, CEO Musk says »

Comparing to Nvidia…

TSLA

Tesla

$263.10

-10.15 (-3.71%)

NVDA

Nvidia

$188.97

2.71 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 22

    May

  • 10

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
04/22/19
04/22
15:17
04/22/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
04/22/19
04/22
15:16
04/22/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$263.15

-10.1 (-3.70%)

15:07
04/22/19
04/22
15:07
04/22/19
15:07
Hot Stocks
All Tesla cars being produced have all necessary for full self-driving »

Says people will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

WILC

G. Willi-Food

$8.30

(0.00%)

15:04
04/22/19
04/22
15:04
04/22/19
15:04
Hot Stocks
G. Willi-Food signs memorandums of understanding for potential acquisitions »

G. Willi-Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$46.77

-0.54 (-1.14%)

15:04
04/22/19
04/22
15:04
04/22/19
15:04
Options
Zions Bancorp options imply 4.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

CGC

Canopy Growth

$47.98

3.55 (7.99%)

15:00
04/22/19
04/22
15:00
04/22/19
15:00
Options
Buyers gobble up Canopy Growth calls as shares light up »

Buyers gobble up Canopy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$264.00

-9.25 (-3.39%)

14:59
04/22/19
04/22
14:59
04/22/19
14:59
Hot Stocks
Tesla highlights security of FSD computer »

Says if software is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

TSLA

Tesla

$263.58

-9.67 (-3.54%)

14:54
04/22/19
04/22
14:54
04/22/19
14:54
Hot Stocks
'Any part could fail,' car will keep driving, Tesla CEO says »

Tesla CEO highlights…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.